Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
Krishnan, Biju
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. [electronic resource] - British journal of haematology Jun 2010 - 907-10 p. digital
Publication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't
1365-2141
10.1111/j.1365-2141.2010.08134.x doi
Adult
Aged
Alemtuzumab
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--therapeutic use
Antineoplastic Agents--therapeutic use
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation--methods
Humans
Leukemia, Prolymphocytic, T-Cell--therapy
Male
Middle Aged
Retrospective Studies
Survival Analysis
Treatment Outcome
Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. [electronic resource] - British journal of haematology Jun 2010 - 907-10 p. digital
Publication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't
1365-2141
10.1111/j.1365-2141.2010.08134.x doi
Adult
Aged
Alemtuzumab
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--therapeutic use
Antineoplastic Agents--therapeutic use
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation--methods
Humans
Leukemia, Prolymphocytic, T-Cell--therapy
Male
Middle Aged
Retrospective Studies
Survival Analysis
Treatment Outcome